Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2

Status

Completed 5Active not recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Head & Neck 2Genitourinary 1Dermatologic 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Melanoma 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × INDUSTRY × soluble LAG-3 protein, human × Clear all
NCT03625323 2026-04-22

TACTI-002

Immutep S.A.S.

Phase 2 Completed
187 enrolled 13 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04811027 2025-12-11

TACTI-003

Immutep S.A.S.

Phase 2 Completed
171 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02676869 2019-12-18

TACTI-mel

Immutep Australia Pty. Ltd.

Phase 1 Completed
24 enrolled
Dermatologic

Melanoma

NCT00349934 2010-01-07

IMP321 Plus First-line Paclitaxel in Metastatic Breast Carcinoma

Immutep S.A.S.

Phase 1 Completed
33 enrolled
Breast

Breast Neoplasms

NCT00351949 2010-01-07

IMP321 Phase 1 Trial in Metastatic Renal Cell Carcinoma (MRCC)

Immutep S.A.S.

Phase 1 Completed
24 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡